AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8863869
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) infusions 1 g kg‐1 (n = 23)
Trial: 8863869
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone pulse therapy (MPPT) 30 mg kg‐1 (n = 20)
Trial: 8863869
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone pulse therapy (MPPT)
Trial: 1480736
Drug: HAL DIRS‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAL DIRS‐C (Drug Impairment Rating Scale for Cocaine) administered weekly
Trial: 27766596
Drug: Both acupuncture
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both acupuncture treatments
Trial: 24217938
Drug: Oral metformin
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metformin (1,500 mg to 2,000 mg daily)
Trial: 24217938
Drug: Increased insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased insulin dose (control group)
Trial: 21083860
Drug: Oral metformin
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metformin
Trial: 20364382
Drug: Cytoreductive nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive nephrectomy and cytokine therapy
Trial: 16847636
Drug: Tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen citrate (TMX) at a 20-mg dosage
Trial: 16847636
Drug: No ovulation-induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ovulation-induction drugs (Control)
Trial: 12787038
Drug: Systemic corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroid therapy with prednisone (50 mg/day) followed by clobetasol ointment plus antimycotics
Trial: 12787038
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with clobetasol plus antimycotics
Trial: 11068775
Drug: Daily ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ATG (DATG)
Trial: 3069682
Drug: Labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200 mg twice a day)
Trial: 6094076
Drug: Hydrochlorothiazide (HCTZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ), 25 mg twice a day (group 1; n = 12)
Trial: 6094076
Drug: Enalapril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 10 mg twice a day (group 2; n = 12)
Trial: 6094076
Drug: Enalapril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 10 mg twice a day, with HCTZ, 25 mg twice a day (group 3; n = 5)
Trial: 24534142
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg once daily (OD)
Trial: 24534142
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg three times daily (TID)
Trial: 24534142
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg OD
Trial: 24534142
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg TID
Trial: 17387132
Drug: Tilarginine (1‐mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilarginine (1‐mg/kg bolus and 1‐mg/kg per hour 5‐hour infusion)
Trial: 16229112
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Trial: 16229112
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Trial: 11603414
Drug: Human polyvalent
RxNorm normalized name: Human polyvalent shedded antigen vaccine
DrugBank: Seviprotimut-L (DB16328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human polyvalent immunoglobulin for intravenous administration
Trial: 11603414
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immunoglobulin and plasmapheresis
Trial: 8890204
Drug: CVD 1203
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 1203 vaccine (1.5 x 10^8 CFU)
Trial: 8890204
Drug: CVD 1203
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 1203 vaccine (1.5 x 10^9 CFU)
Trial: 8890204
Drug: CVD 1203
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 1203 vaccine (1.2 x 10^6 CFU)
Trial: 8890204
Drug: CVD 1203
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 1203 vaccine
Trial: 30618054
Drug: AZD4831 135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 135 mg
Trial: 30618054
Drug: AZD4831 405
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 405 mg
Trial: 30618054
Drug: AZD4831 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 (all doses)
Trial: 22497598
Drug: Ribosomal prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribosomal prophylaxis with Immucytal® (one tablet daily, 8 days a month for 3 months)
Trial: 17126918
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosage for the same period)
Trial: 10527226
Drug: Rocuronium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 1.0 mg/kg
Trial: 7902034
Drug: Succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0 mg/kg
Trial: 2186020
Drug: Clonazepam (0.5-2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.5-2.0 mg/day)
Trial: 2186020
Drug: Imipramine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (25-50 mg/day)
Trial: 31713469
Drug: Carbapenem long-lasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenem long-lasting (4h) infusion
Trial: 27755109
Drug: Sorafenib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib treatment
Trial: 28052588
Drug: Sirukumab 50
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 50 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Trial: 28052588
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Trial: 28052588
Drug: Sirukumab 50
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 50 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Trial: 28052588
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Trial: 28052588
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg intravenous (IV) infusion
Trial: 28052588
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg by PFS‐AI
Trial: 11713920
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of atropine sulfate
Trial: 7904003
Drug: Intranasal spray
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray
Trial: 2923763
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg i.v. in 5% dextrose 20 ml
Trial: 786352
Drug: Practolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (120 mg)
Trial: 23320650
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (4930 mg = 20 mmol magnesium) administered 60 min before and 6 hours after ERCP
Trial: 23320650
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 60 min before and 6 hours after ERCP
Trial: 17890730
Drug: Low-dose INR
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose INR self-management
Trial: 15481562
Drug: Low-intensity home-based
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity home-based physical therapy (once a week for 10 weeks)
Trial: 11853284
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (Hyalgan 2 ml/wk for 4 doses)
Trial: 11853284
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml of normal saline)
Trial: 9763324
Drug: Electric toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9)
Trial: 9763324
Drug: Electric toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric toothbrush (Braun/Oral-B Plaque Remover-D7)
Trial: 9763324
Drug: Electric toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9) with different types of endrounding
Trial: 9763324
Drug: Electric toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric toothbrush (Braun/Oral-B D7 at 2800 rot/min) and D9 at 3600 rot/min
Trial: 7825006
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or intravenous rehydration (Control)
Trial: 3254767
Drug: Oral high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral high-frequency oscillation (OHFO) at 8 Hz
Trial: 3254767
Drug: Oral high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral high-frequency oscillation (OHFO) at 16 Hz
Trial: 3254767
Drug: Oral high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral high-frequency oscillation (OHFO) at 8 Hz, 12 Hz, and 16 Hz
Trial: 31462117
Drug: Oral Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tramadol 50 mg, 1 hour prior to the procedure
Trial: 23640072
Drug: AZD1446 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1446 80 mg qd
Trial: 23640072
Drug: AZD1446 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1446 (80 mg tid, 80 mg qd, 10 mg tid)
Trial: 12699447
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (5 mg/day, n = 10)
Trial: 31900204
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of lopinavir/ritonavir and recombinant interferon-Î²1b with standard supportive care
Trial: 23610239
Drug: Aliskiren 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 2 mg/kg
Trial: 23610239
Drug: Aliskiren 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 6 mg/kg
Trial: 21362527
Drug: Coping skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping skills training (CST) intervention: 16 weekly 30-minute telephone counseling sessions including motivational interviewing and individually tailored cognitive behavioral therapy.
Trial: 21362527
Drug: Heart failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart failure education (HFE) intervention: 16 weekly 30-minute telephone sessions including education and symptom monitoring.
Trial: 18204042
Drug: Hypoglycaemia (nadir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (nadir P-glucose 2.7 +/- 0.5 mmol/L)
Trial: 14657064
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist strategy (CAS) - verapamil sustained release
Trial: 14657064
Drug: Non-calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-calcium antagonist strategy (NCAS) - atenolol
Trial: 11049918
Drug: Droperidol (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (0.625 mg IV)
Trial: 11049918
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg IV)
Trial: 11049918
Drug: Promethazine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (12.5 mg IV)
Trial: 8713784
Drug: Intralipid 20%
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 20% infusion (n = 5)
Trial: 8713784
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% infusion (n = 5)
Trial: 1569339
Drug: Low-dose amphotericin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amphotericin B (serum concentrations of 0.2-0.4 microgram/ml)
Trial: 1569339
Drug: Low-dose amphotericin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amphotericin B
Trial: 29669617
Drug: Modified mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified mindfulness-based cognitive therapy (MBCT) course, comprising eight weekly 2-hour sessions with homework (mindfulness practice) between sessions.
Trial: 20420997
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination in deltoid muscle
Trial: 20420997
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination in vastus lateralis
Trial: 18524727
Drug: Propafenone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (300 mg/day)
Trial: 18524727
Drug: Sotalol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (80 mg/day)
Trial: 8160602
Drug: Amiodarone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (400 mg/day)
Trial: 6407453
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg/day)
Trial: 18524727
Drug: No anti-arrhythmic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-arrhythmic drugs (Control Group)
Trial: 10608204
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg and chlorpheniramine maleate (CPM) 20 mg i.m.
Trial: 10608204
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 20 mg CPM i.m. alone
Trial: 1812425
Drug: Outer membrane
RxNorm normalized name: Outer membrane protein 3B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outer membrane vesicle vaccine
Trial: 7023791
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of aluminum hydroxide gel (fasting)
Trial: 7023791
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml magnesium hydroxide suspension (fasting)
Trial: 7023791
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of aluminum hydroxide gel (fed)
Trial: 7023791
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of aluminum hydroxide/magnesium hydroxide mixture (fed)
Trial: 7023791
Drug: Fasted, no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted, no antacid
Trial: 7023791
Drug: Fed, no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed, no antacid
Trial: 28103623
Drug: Excess fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excess fatty acid (24hFA) treatment
Trial: 28103623
Drug: Fenofibrate treatment
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate treatment in vivo
Trial: 26374702
Drug: subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous interferon (IFN) β‐1a
Trial: 21632446
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) 50,000 U weekly for 8 doses, then 10,000 U weekly
Trial: 20027096
Drug: Postoperative analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesics
Trial: 11597802
Drug: Oral sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sucralfate (3 g suspension, twice a day during radiotherapy)
Trial: 11597802
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice a day during radiotherapy)
Trial: 11597802
Drug: Oral sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sucralfate
Trial: 9834047
Drug: Anticonvulsant drugs
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant drugs (specific drugs not mentioned)
Trial: 8003559
Drug: Thiotepa 450‐750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotepa 450‐750 mg/m2, busulfan 10 or 12 mg/kg, and cyclophosphamide 120 or 150 mg/kg
Trial: 8003559
Drug: Higher busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Higher busulfan dose
Trial: 8003559
Drug: Ten or
RxNorm normalized name: Egaten Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten or more previous cycles of chemotherapy
Trial: 2589355
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin and azlocillin
Trial: 913868
Drug: Delta‐Butazolidin (phenylbutazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta‐Butazolidin (phenylbutazone 50 mg + prednisone 1.25 mg)
Trial: 913868
Drug: Prednisone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 1.25 mg
Trial: 27471840
Drug: Prophylactic augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic augmentation with retro-muscular lightweight polypropylene mesh
Trial: 25988261
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1500 mg quercetin
Trial: 25988261
Drug: Short-term administration
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term administration of 1500 mg quercetin daily for 1 week
Trial: 25988261
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of midazolam
Trial: 19500787
Drug: 7-day low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day low-dose omeprazole infusion (3.3 mg/h)
Trial: 19500787
Drug: 3-day high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day high-dose omeprazole infusion (8 mg/h)
Trial: 19500787
Drug: 7-day low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day low-dose omeprazole infusion
Trial: 16514327
Drug: Lidocaine 5
RxNorm normalized name: lidocaine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 5 mg/kg/h
Trial: 16514327
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mg/kg/h
Trial: 16514327
Drug: Lidocaine 3
RxNorm normalized name: Lidocaine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 3 mg/kg/h
Trial: 11085201
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 to 300 mg/day for 6 to 10 weeks